Understanding how T cell receptors recognize tumor antigens
MATCHMAKERS - Solving TCR recognition and design via integrated high-throughput screening, structural, functional, and computational approaches
['FUNDING_OTHER'] · CHILDREN'S HOSP OF PHILADELPHIA · NIH-11047204
This study is looking at how T cells recognize cancer markers to help make immunotherapy treatments more effective, and it aims to create better ways to predict how these T cells will respond to different tumors, which could lead to more personalized and successful treatments for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CHILDREN'S HOSP OF PHILADELPHIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11047204 on ClinicalTrials.gov |
What this research studies
This research investigates how T cell receptors (TCRs) identify tumor antigens presented by MHC molecules, which is crucial for enhancing immunotherapy effectiveness. By leveraging advanced machine learning techniques and extensive datasets of TCR-pMHC pairs, the project aims to develop accurate predictors for TCR-antigen recognition. The research involves collaboration among experts in immunology, structural biology, and computational methods to create a comprehensive understanding of TCR interactions. Patients may benefit from improved immunotherapy strategies tailored to their specific tumor profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancers who may benefit from targeted immunotherapy.
Not a fit: Patients with non-malignant conditions or those not eligible for immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized immunotherapies for cancer patients.
How similar studies have performed: Previous research has shown promise in using machine learning to enhance immunotherapy, indicating potential success for this novel approach.
Where this research is happening
PHILADELPHIA, UNITED STATES
- CHILDREN'S HOSP OF PHILADELPHIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SGOURAKIS, NIKOLAOS — CHILDREN'S HOSP OF PHILADELPHIA
- Study coordinator: SGOURAKIS, NIKOLAOS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer